The global Induced Pluripotent Stem Cell (IPS cell) market size was valued at US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
Induced pluripotent stem cells (iPS cell), immature cell generated from an adult (mature) cell and has regained the capacity to differentiate into any cell in the body. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially treat previously incurable diseases.
The induced pluripotent stem cell (IPS cell) market growth is driven by the increasing therapeutic advancements with iPS Cell, growing mergers and acquisitions of organizations to expand their portfolio in iPSCs, and Increasing research activities are the major driving factors of the market.
A strong pipeline of iPSC is expected to drive the growth of the global induced pluripotent stem cell (IPS cell) market during the forecasting period.
The prevalence of chronic diseases worldwide is driving many vendors in the market to develop novel induced pluripotent stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, I Peace Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapy for heart failure. I Peace is generating the GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology. Its facility is equipped with the fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.
Hopstem Biotechnology is one of China’s first iPSC cell therapy companies and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy to treat ocular diseases. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming method, and GMP manufactory and quality systems.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/induced-pluripotent-stem-cell-market
- Human iPSCs
- Mouse iPSCs
- Academic Research
- Drug Development and Discovery
- Toxicity Screening
- Regenerative Medicine
The global induced pluripotent stem cell (ips cell) market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
For instance, Cynata Therapeutics manufactures iPSC-derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.